AstraZeneca and Bristol Myers Squibb have engaged in preliminary merger talks that could create a pharmaceutical company valued near US$400 billion. The prospective deal reflects an accelerating wave of pharma consolidation, with global sector M&A reaching US$134 billion in the first half of 2026, and would face antitrust review over overlapping oncology portfolios.
AstraZeneca and Bristol Myers Squibb have held preliminary talks about a merger that could create a company worth close to US$400 billion. If completed, the combination would rank among the largest transactions in pharmaceutical industry history and would carry implications for markets where both companies maintain substantial operations. The discussions, which sources say have continued for several months, could still collapse or be delayed, and neither company has confirmed them.
The reported approach follows a broader realignment in AstraZeneca’s strategy toward the US market. The company completed a direct listing of its shares on the New York Stock Exchange earlier this year, and the US accounted for 42% of its total sales in the first half of 2026, according to figures reported by CNBC. Under Chief Executive Officer Pascal Soriot, who has led the company since 2012 and previously rejected a US$119 billion takeover approach from Pfizer in 2014, AstraZeneca has set a target of US$80 billion in annual revenue by 2030, up from US$58.7 billion the previous year .Bristol Myers Squibb is contending with the coming loss of patent exclusivity on two of its largest products, cancer immunotherapy Opdivo and blood thinner Eliquis, both considered vulnerable to generic competition by 2028.
A combination would also arrive amid the most active period for pharmaceutical dealmaking in years. Global pharma and biotech transactions reached US$134 billion in the first half of 2026, already surpassing the full-year 2025 total of US$112 billion, industry trackers reported. Should AstraZeneca and Bristol Myers Squibb proceed, the deal would need to clear antitrust review on both sides of the Atlantic, given overlapping oncology portfolios. AstraZeneca’s cancer treatments generated roughly US$25 billion last year, close to half of its total revenue, while oncology represented more than 40% of Bristol Myers Squibb’s sales through the first half of 2026.
For Mexico, the outcome of the talks carries direct relevance. Both companies rank among the pharmaceutical multinationals that have expanded local footprints as part of the industry’s push to diversify manufacturing and research capacity. Bristol Myers Squibb has committed nearly MX$1 billion (US$53.6 million) over four years to clinical research in cardiovascular disease, immunology, hematology, and oncology in Mexico, part of a broader package of more than MX$21 billion in pharmaceutical investment commitments announced this year by companies including Abbott, Sanofi, and Liomont. AstraZeneca has separately built out manufacturing capacity in the State of Mexico and expanded its Global Innovation and Technology Center in Guadalajara, positioning the country within its global operating network.
A merger of this scale would also land against the backdrop of an increasingly consolidation-driven corporate landscape in Mexico. The country’s mergers and acquisitions market grew 21% to US$10.91 billion in the first half of 2026, even as deal volume contracted, reflecting a shift toward fewer but larger strategic transactions. A pharmaceutical merger of the scale being discussed by AstraZeneca and Bristol Myers Squibb would stand apart from, but consistent with, that broader pattern of capital concentrating in larger, strategically significant deals.
A merger would also reshape the innovation map both companies have built in Mexico over decades. AstraZeneca and Bristol Myers Squibb have each operated in the country for well over 70 years, running dozens of active clinical trials in partnership with institutions such as UNAM, IPN, and IMSS. Combining research pipelines, oncology franchises, and manufacturing footprints of that scale would likely require regulators and local partners to review how ongoing commitments, from clinical studies to job creation targets, would be affected during any integration process, even though such details would only be settled once, and if, a transaction is formally agreed.
For now, the outcome remains uncertain. Both companies have declined to comment publicly. Should the talks advance, the structure would likely combine cash and stock, though final terms have not been determined. Industry watchers are expected to look for further signals in the coming weeks, particularly around whether either company issues a formal statement or files disclosures with securities regulators in the United Kingdom or the United States.